Cellares, a pioneer in cell therapy manufacturing, has bolstered its financial standing with a $50 million growth equity investment from Prime Radiant Partners. This latest infusion extends the company's Series D financing to a total of $327 million. The funding is earmarked to advance Cellares' global expansion, particularly in Europe, and to finance its operations through a planned initial public offering in 2027.
Strategic Investment for European Expansion
The investment from Prime Radiant Partners is a strategic move, leveraging the firm's deep expertise in European pharmaceutical services. Walid Gardezi, Co-Founder of Prime Radiant, emphasized that Cellares is building the necessary infrastructure to support cell therapy's transition from scientific promise to commercial reality. The partnership aims to actively support Cellares' growth and operational capabilities across the continent as it establishes its manufacturing presence.
A key component of this expansion is the construction of a new Smart Factory in Leiden, the Netherlands, which is slated to be GMP-ready in 2027. This facility will feature the same automated manufacturing technology available in the United States, enabling Cellares to serve drug sponsors across global markets. The new site is critical to meeting the growing regional demand for automated cell therapy production.
Bolstering a Global Manufacturing Network
Cellares CEO Fabian Gerlinghaus highlighted the necessity of building a comprehensive global cell therapy manufacturing network across all major markets simultaneously. He noted that Prime Radiant's operational depth in Europe makes them an ideal strategic partner for this ambitious phase of growth. The strong syndicate of investors in the Series D round underscores confidence in the company's platform and its future scalability.
The company's manufacturing platform is already gaining significant commercial traction with a diverse pipeline of active programs. Cellares is engaged with prominent drug sponsors, including Bristol Myers Squibb, Cabaletta Bio, and TScan Therapeutics, across various therapy types. This is further validated by a $380 million global manufacturing agreement with Bristol Myers Squibb and a 10-year supply agreement with Cabaletta Bio.
The Technology Driving Scalability
At the heart of Cellares' operation is its proprietary Cell Shuttle® platform, a fully automated system for end-to-end cell therapy manufacturing. This technology, which has received the FDA's Advanced Manufacturing Technology designation, enables the production of up to ten times more therapy batches than conventional methods. This efficiency significantly reduces manufacturing costs and improves process success rates, addressing key industry bottlenecks.
The platform has successfully transitioned from a developmental technology to clinically validated infrastructure, a crucial milestone for the company. This validation was achieved through the successful dosing of the first patients in a partner's clinical trial using therapies produced on the Cell Shuttle. The achievement spans multiple therapeutic areas, including both oncology and autoimmune indications, proving its versatility and reliability.
With its Series D financing now totaling $327 million, Cellares is strongly positioned to tackle the critical manufacturing challenges facing the cell therapy sector. The strategic investment from Prime Radiant Partners will accelerate its European expansion and solidify its global footprint ahead of a planned 2027 IPO. This progress is a significant step toward the company's ultimate goal of expanding patient access to life-saving cell therapies worldwide.